[
  {
    "ts": null,
    "headline": "Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)",
    "summary": "Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug Administration (FDA) approval of OSVYRTI® (denosumab-desu), a biosimilar to Prolia® (denosumab), and JUBEREQ® (denosumab-desu), a biosimilar to Xgeva® (denosumab).1-2 The dual approvals mark Accord BioPharma's fourth and fifth biosimilars, demonstrating the company's continued growth in the U.S. market.",
    "url": "https://finnhub.io/api/news?id=cc210b73a6da33a9ca0eada82c3746193994a26307056f2c9e543ab79f2e48fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763643900,
      "headline": "Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)",
      "id": 137556504,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug Administration (FDA) approval of OSVYRTI® (denosumab-desu), a biosimilar to Prolia® (denosumab), and JUBEREQ® (denosumab-desu), a biosimilar to Xgeva® (denosumab).1-2 The dual approvals mark Accord BioPharma's fourth and fifth biosimilars, demonstrating the company's continued growth in the U.S. market.",
      "url": "https://finnhub.io/api/news?id=cc210b73a6da33a9ca0eada82c3746193994a26307056f2c9e543ab79f2e48fa"
    }
  },
  {
    "ts": null,
    "headline": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
    "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
    "url": "https://finnhub.io/api/news?id=095930a75826d0aee56911bca29526d07044581e6ef8d98e8f635a494a0c3c96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763643600,
      "headline": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
      "id": 137556460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
      "url": "https://finnhub.io/api/news?id=095930a75826d0aee56911bca29526d07044581e6ef8d98e8f635a494a0c3c96"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Will Wegovy And Pipeline Spark Rally?",
    "summary": "Discover 5+ factors making Novo Nordisk a strong long-term stock pick despite market skepticism.",
    "url": "https://finnhub.io/api/news?id=194d7708f918ec1df5a237a1ccc54ff69f6767151c5969241794ff371de89988",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763643080,
      "headline": "Novo Nordisk: Will Wegovy And Pipeline Spark Rally?",
      "id": 137561050,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1311809105/image_1311809105.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Discover 5+ factors making Novo Nordisk a strong long-term stock pick despite market skepticism.",
      "url": "https://finnhub.io/api/news?id=194d7708f918ec1df5a237a1ccc54ff69f6767151c5969241794ff371de89988"
    }
  },
  {
    "ts": null,
    "headline": "Is Amgen Inc. (NASDAQ:AMGN) A High Quality Stock To Own?",
    "summary": "While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",
    "url": "https://finnhub.io/api/news?id=9954f44831ff5262950eef6428919edb9f4803a21d0dba83be95d58328225325",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763640009,
      "headline": "Is Amgen Inc. (NASDAQ:AMGN) A High Quality Stock To Own?",
      "id": 137556506,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",
      "url": "https://finnhub.io/api/news?id=9954f44831ff5262950eef6428919edb9f4803a21d0dba83be95d58328225325"
    }
  },
  {
    "ts": null,
    "headline": "$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield",
    "summary": "Discover 5 undervalued large-cap health care stocks using a proven screening method.",
    "url": "https://finnhub.io/api/news?id=d057abb57ab8f45949785205029293c9073aa0bb6830b40b53701c1728a2537a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763637427,
      "headline": "$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield",
      "id": 137557117,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Discover 5 undervalued large-cap health care stocks using a proven screening method.",
      "url": "https://finnhub.io/api/news?id=d057abb57ab8f45949785205029293c9073aa0bb6830b40b53701c1728a2537a"
    }
  }
]